The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1958-1968

  Oetzel, Carsten ^b   Jonuleit, Tarja ^a   Götz, Alexander ^a   Van Der Kuip, Heiko ^a   Michels, Heike ^d   Duyster, Justus ^c   Hallek, Michael ^c   Aulitzky, Walter E ^b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Technical University of Munich ^*

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CYTOCHROME C; IMATINIB; JANUS KINASE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CASPASES; CELL COUNT; CELL DIVISION; CHROMONES; CYTOCHROME C GROUP; CYTOSOL; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FAS LIGAND PROTEIN; FLAVONOIDS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MEMBRANE GLYCOPROTEINS; MORPHOLINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0034108115     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Deininger, M. W., and Goldman, J. M. Chronic myeloid leukemia. Curr. Opin. Hematol., 5: 302-308, 1998.
2. Gotoh, A., and Broxmeyer, H. E. The function of BCR/ABL and related proto-oncogenes. Curr. Opin. Hematol., 4: 3-11, 1997.
3. Sanchez-Garcia, I., and Martin-Zanca, D. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J. Mol. Biol., 267: 225-228, 1997.
4. Cortez, D., Stoica, G., Pierce, J. H., and Pendergast, A. M. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene, 13: 2589-2594, 1996.
5. Goga, A., McLaughlin, J., Afar, D. E., Saffran, D. C., and Witte, O. N. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell, 82: 981-988, 1995.
6. Chai, S. K., Nichols, G. L., and Rothman, P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol., 159: 4720-4728, 1997.
7. Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M. Z., Wen, S. C., Zon, G., Gewirtz, A. M., Perussia, B., and Calabretta, B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood, 86: 726-736, 1995.
8. Sattler, M., and Salgia, R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev., 8: 63-79, 1997.
9. Amarante-Mendes, G. P., McGahon, A. J., Nishioka, W. K., Afar, D. E., Witte, O. N., and Green, D. R. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene, 16: 1383-1390, 1998.
10. Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Science (Washington DC), 247: 1079-1082, 1990.
11. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
12. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
13. Deininger, M. W., Goldman, J. M., Lydon, N., and Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90: 3691-3698, 1997.
14. Gambacorti-Passerini, C., le, C. P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di, N. M., Biondi, A., Corneo, G. M., Belotti, D., Pogliani, E., and Lydon, N. B. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis., 23: 380-394, 1997.
15. Hallek, M., Danhauser-Riedl, S., Herbst, R., Warmuth, M., Winkler, A., Kolb, H. J., Druker, B., Griffin, J. D., Emmerich, B., and Ullrich, A. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br. J. Haematol., 94: 5-16, 1996.
16. Bai, R. Y., Jahn, T., Schrem, S., Munzert, G., Weidner, K. M., Wang, J. Y., and Duyster, J. The SH2-containing adapter protein GRB10 interacts with bcr-abl. Oncogene, 17: 941-948, 1998.
17. Schwab, R., Peschel, C., Despres, D., Derigs, G., Fischer, T., Huber, C., and Aulitzky, W. E. Deficient cell cycle control in myeloid cells of patients with newly diagnosed chronic myeloid leukemia. Cytokines Mol. Ther., 1: 281-288, 1995.
18. Wetzler, M., Talpaz, M., Van, E. R., Hirsh-Ginsberg, C., Beran, M., and Kurzrock, R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J. Clin. Invest., 92: 1925-1939, 1993.
19. Peschel, C., Paul, W. E., Ohara, J., and Green, I. Effects of B cell stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells. Blood, 70: 254-263, 1987.
20. Gordon, M. Y., Dowding, C. R., Riley, G. P., and Greaves, M. F. Characterisation of stroma-dependent blast colony-forming cells in human marrow. J. Cell. Physiol., 130: 150-156, 1987.
21. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
22. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
23. Martins, L. M., Mesner, P. W., Kottke, T. J., Basi, G. S., Sinha, S., Tung, J. S., Svingen, P. A., Madden, B. J., Takahashi, A., McCormick, D. J., Earnshaw, W. C., and Kaufmann, S. H. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90: 4283-4296, 1997.
24. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
25. Sirard, C., Laneuville, P., and Dick, J. E. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood, 83: 1575-1585, 1994.
26. Zamzami, N., Brenner, C., Marzo, I., Susin, S. A., and Kroemer, G. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene, 16: 2265-2282, 1998.
27. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
28. Albrecht, T., Schwab, R., Henkes, M., Peschel, C., Huber, C., and Aulitzky, W. E. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br. J. Haematol., 95: 501-507, 1996.
29. Amos, T. A., Lewis, J. L., Grand, F. H., Gooding, R. P., Goldman, J. M., and Gordon, M. Y. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation. X-irradiation and glucocorticoids. Br. J. Haematol., 91: 387-393, 1995.
30. Bedi, A., Zehnbauer, B. A., Collector, M. I., Barber, J. P., Zicha, M. S., Sharkis, S. J., and Jones, R. J. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood, 81: 2898-2902, 1993.
31. Jonuleit, T., Peschel, C., Schwab, R., van, d. K., Buchdunger, E., Fischer, T., Huber, C., and Aulitzky, W. E. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br. J. Haematol., 100: 295-303, 1998.
32. Sawyers, C. L., McLaughlin, J., Goga, A., Havlik, M., and Witte, O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell, 77: 121-131, 1994.
33. Amarante-Mendes, G. P., Naekyung, K. C., Liu, L., Huang, Y., Perkins, C. L., Green, D. R., and Bhalla, K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood, 91: 1700-1705, 1998.
34. Nishii, K., Kabarowski, J. H., Gibbons, D. L., Griffiths, S. D., Titley, I., Wiedemann, L. M., and Greaves, M. F. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene, 13: 2225-2234, 1996.
35. Sanchez-Garcia, I., and Grutz, G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc. Natl. Acad. Sci. USA, 92: 5287-5291, 1995.
36. Lord, J. D., McIntosh, B. C., Greenberg, P. D., and Nelson, B. H. The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc. J. Immunol., 161: 4627-4633, 1998.
37. Suzuki, J., Kaziro, Y., and Koide, H. Synergistic action of R-Ras and IGF-1 on Bcl-xL expression and caspase- 3 inhibition in Ba/F3 cells: R-Ras and IGF-1 control distinct anti- apoptotic kinase pathways. FEBS Lett., 437: 112-116, 1998.
38. Packham, G., White, E. L., Eischen, C. M., Yang, H., Parganas, E., Ihle, J. N., Grillot, D. A., Zambetti, G. P., Nunez, G., and Cleveland, J. L. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev., 12: 2475-2487, 1998.